Investigational Site Number : 1240002

London, Ontario N6H 5L5

3 studies enrolling now · 5 studies all time

What they study most

Chronic Obstructive Pulmonary Disease, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Hidradenitis Suppurativa, Pruritus, Transplant Rejection

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) — Recruiting now
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — Recruiting now
• BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) — Running, not enrolling
• A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa — Completed